Basilea 开始对抗真菌药物进行第三期研究,用于治疗成人严重的真菌感染. Basilea launches Phase 3 study for antifungal drug to treat severe mold infections in adults.

药业公司 Basilea Pharmaceutica 已启动其抗真菌药物 fosmanogepix 的第三期研究,用于治疗成年人侵袭性真菌感染. Basilea Pharmaceutica has launched a Phase 3 study for its antifungal drug fosmanogepix to treat invasive mold infections in adults. FORWARD-IM研究旨在评估该药物的安全和有效性,重点是因这种感染而面临高死亡率的免疫杂乱病人。 The FORWARD-IM study aims to assess the drug's safety and effectiveness, focusing on immunocompromised patients who face high mortality rates from such infections. fosmanogepix 预计将于 2028 年第一季度结束，已获得 FDA 快速通道和孤儿药认定，用于多个适应症。 Expected to conclude in the first quarter of 2028, fosmanogepix has already received FDA Fast Track and Orphan Drug designations for several indications.